NEW YORK, March 22, 2018 /PRNewswire/ -- Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national shareholder andconsumer rights litigation firm, is investigating whether Solid Biosciences Inc. ("Solid Biosciences" or the "Company") (NASDAQ: SLDB) or certain of its officers and directors violated federal securities laws. If you are a Solid Biosciences shareholder,
Solid Biosciences is a biotechnology company that develops therapies and devices for patients with duchenne muscular dystrophy ("DMD").
On March 14, 2018, the Company announced it received notification from the U.S. Food and Drug Administration ("FDA") that IGNITE DMD, its Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in DMD, had been placed on Clinical Hold.
On this news, shares of Solid Biosciences fell $16.99 per share over 64% to close at $9.32 on March 15, 2018.
The Company held its initial public offering ("IPO") on January 26, 2018 at $16 per share; since then, the stock price has fallen nearly 47% as of market close on March 21, 2018.
What You Can Do
If you are a Solid Biosciences shareholder and you suffered a loss, and you wish to discuss this investigation, please contact attorney Joe Pettigrew at (844) 818-6982, or at firstname.lastname@example.org.
About Scott+Scott Attorneys at Law LLP
Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.
Joe PettigrewScott+Scott Attorneys at Law LLP230 Park Ave, 17th Fl, NY, NY 10169(844) email@example.com
View original content:http://www.prnewswire.com/news-releases/scottscott-attorneys-at-law-llp-announces-investigation-into-solid-biosciences-inc-sldb-300618379.html
SOURCE Scott+Scott Attorneys at Law LLP
Subscribe to our Free Newsletters!